Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fundación Renal Iñigo Alvarez De Toledo
With
Effice Servicios Para la Investigacion S.L.
Clinical Trial to estimate UACR determined albuminuria differences between treatment and non-treatment groups from basal intake to last study-related observation. Patients should suffer proteinuric Chronical Kidney Disease and recovered levels of seric 25(OH)D. Also, this clinical trial tries to determinate the effect of paricalcitol over several metabolic and inflammatory parameters on patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent signed
Patients will be men or women, between 18 and 75 years old.
Patients must have been taken an stable dosis of Angiotensine Converter Enzyme Inhibitor, Angiotensine Receptor Antagonism or antialdosterone at last 6 months before screening visit.
Patients should not be on dialysis treatment.
Women should not be pregnant, or in fertile period (at last 1 year postmenopausal or chirurgic sterilized or using this contraceptive methods: condoms, gel, intrauterine devices, anticonceptives, etc. During at last 3 months after the study beginning.
You may not be if
Patients have taken active vitamin D during 6 months after the screening.
Patients with allergy o sensibility to paricalcitol.
Patients with acute CKD 12 weeks before the screening.
Patients with chronical gastrointestinal disease.
Patients with hypo or hyperthyroidism.
Patients with secondary hypertension
Bad controled hypertension patients
Patients with renal lithiasis
Patients with drug dependence
Patients taking calcitonins, biphosphonates, cinacalcet or others Ca-metabolism drugs.
Patients taking immunosuppressor drugs.
Patients not adequate to study as medical opinion.
